A cash-backed biotech “call option” trying to resurrect simufilam via an orphan-epilepsy pivot—blocked (for now) by a decisive FDA clinical hold.
Overview
Cassava Sciences (SAVA) is a pre-revenue, Austin-based clinical-stage biotech that has undergone a major reset after the definitive failure of its Phase 3 Alzheimer’s program (RETHINK-ALZ and REFOCUS-ALZ) in late 2024–early 2025. The company’s core asset, simufilam—an oral small molecule intended to modulate/stabilize Filamin A (FLNA)—did not demonstrate clinically validated cognitive benefit in Alzheimer’s, but the large Phase 3 experience (nearly 2,000 patients) produced a substantial safety database showing generally favorable tolerability. Cassava is now attempting to salvage the FLNA platform by pivoting to Tuberous Sclerosis Complex (TSC)-related epilepsy, a rare-disease setting with high unmet need (seizures in ~80–90% of TSC patients; ~60% inadequately controlled on current therapies). The investment case is dominated by regulatory gating: an FDA **full clinical hold (Dec 2025)** currently prevents initiation of the planned Phase 2 study, making remediation and hold removal the key near-term catalysts. Financially, SAVA is essentially a cash-backed option on clinical success, with no revenue and valuation near cash value.